Building Hope.

Trovagene is developing precision cancer therapeutics to improve cancer care.

Our Mission

Our mission is to transform cancer therapeutics to improve cancer care.

Our Therapeutics

We are a clinical stage precision medicine biotechnology company developing oncology therapeutics for hematologic and solid tumor cancers. Beginning with our lead drug candidate PCM-075, a Polo-like Kinase 1 (PLK1) Inhibitor, we are on a journey to develop new treatment options to help transform cancer care.

PCM-075 is the first PLK1 inhibitor of its kind to enter clinical trials. Now with the FDA’s granting of orphan drug designation for PCM-075 to treat patients with Acute Myeloid Leukemia (AML), and initiation of our Phase 1b/2 clinical trial, we are moving forward with our clinical development program.

We optimize drug development by leveraging our significant experience and expertise in biomarker and Precision Cancer Medicine® (PCM) technology to address the need for new therapeutic options to treat hematologic and solid tumor cancers.

What is PCM-075, a PLK1 Inhibitor?

PCM-075 is the first PLK1 inhibitor of its kind to enter clinical trials. It is an oral, highly selective competitive inhibitor of the PLK1 enzyme which is commonly overexpressed in several different hematologic and solid tumor cancers.

These attributes combined with potential synergy in combination with numerous chemotherapeutics and targeted therapies makes PCM-075 a highly attractive drug candidate.

Orphan Drug Designation in AML

On September 28th, 2017, the FDA granted Orphan Drug Designation to our PLK1 inhibitor, PCM-075 for the treatment of Acute Myeloid Leukemia, an important milestone in our clinical development plan.

PCM-075 Clinical Evidence

PCM-075 has the potential to be a safe and effective treatment for hematologic and solid tumor cancers due to high selectivity for PLK1, relatively short half-life, and more.

Combination Therapy Opportunities

PCM-075 may be synergistic and enhance the efficacy of current and future standard-of-care therapies.

In Our Pipeline

We are developing PCM-075 for both hematologic and solid tumor cancers. Our Precision Cancer Medicine® technology allows us to measure genetic fragments of cancer tumors to identify patients most likely to respond to therapy.

News

Sep 5, 2018

Trovagene Announces Predictive Clinical Biomarker Approach to Identify Acute Myeloid Leukemia (AML) Patients Most Likely to Respond to Onvansertib

Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs for the treatment of leukemias, lymphomas and solid tumor…

Learn More

Aug 29, 2018

Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe

Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs for the treatment of leukemias, lymphomas and solid tumor…

Learn More

Aug 16, 2018

Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial

Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, today announced…

Learn More